The initiative could bring welcome relief to patients, but it also exposes the Government to a difficult question.
Can medicine prices be controlled without disrupting supply?
NMRA Chairman Ananda Wijewickrama says the regulator expects to determine prices for the majority of medicines actively imported into the country over the next year.
The exercise covers more than 6,000 registered formulations and is being conducted on a brand-by-brand basis as pharmaceutical companies apply for annual import licences.
The scale of the undertaking is significant.
A single medicine may have dozens of competing brands, each requiring a separate determination. Metformin, for instance, is registered under more than 30 brand names, according to Wijewickrama.
The policy is designed to remove pricing inconsistencies and prevent consumers from paying excessive amounts for identical products.
At present, the same medicine can be sold at different prices in Colombo, Jaffna, Anuradhapura and other areas.
A standardised MRP could therefore create greater national consistency and make it easier for consumers to identify unreasonable charges.
Publishing approved prices on the NMRA website could further strengthen transparency. Patients, doctors and pharmacies would have a publicly available benchmark against which retail prices could be checked.
Hitherto the policy could also expose weaknesses in Sri Lanka’s pharmaceutical supply chain if price controls become too rigid.
The most obvious danger is product withdrawal. Pharmaceutical companies are unlikely to continue supplying a small market indefinitely if regulatory prices prevent them from covering legitimate costs.
International suppliers can redirect products to other markets rather than accept sustained losses in Sri Lanka.
This creates a classic regulatory dilemma.
The Government must protect consumers from profiteering while ensuring that pharmaceutical companies retain sufficient commercial incentives to keep importing medicines.
The NMRA appears conscious of another potential problem—artificially inflated import prices. It plans to compare declared CIF import costs with domestic retail prices in countries where the medicines are manufactured, including India and Bangladesh.
Such benchmarking could help identify inflated transfer pricing and prevent excessive costs being passed on to Sri Lankan consumers.
But pharmaceutical pricing is affected by more than the factory price.
Freight, insurance, currency movements, regulatory costs and distribution expenses can change substantially. The NMRA therefore intends to keep prices under review and adjust them according to raw-material costs and exchange-rate changes.
That flexibility will be critical.
A fixed ceiling that fails to reflect rising import costs could eventually encourage suppliers to reduce shipments, discontinue brands or avoid the market altogether.
The Government must therefore resist the temptation to measure success purely through lower MRPs.
The real test is whether patients obtain medicines at affordable prices without facing shortages, disappearing brands or reduced competition.
Sri Lanka needs medicine-price regulation, but it needs intelligent regulation. The objective should not simply be cheaper medicines on paper.
It should be a stable pharmaceutical market in which patients receive affordable, quality medicines when they need them.
Leave your comments
Login to post a comment
Post comment as a guest